A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis – Study design and rationale of HM-TRIA-201 study
Manal F. Abdelmalek, Ayako Suzuki, Willian Sanchez, Eric Lawitz, Claudia Filozof, Hyung-Jin Cho, Eunhye Baek, JaeDuk Choi, Seung Jae Baek
Topics & Concepts
MedicineSteatohepatitisPlaceboDouble blind studyInternal medicineRandomized controlled trialMulticenter studyDouble blindGastroenterologyFatty liverPathologyAlternative medicineDiseaseLiver Disease Diagnosis and TreatmentPancreatitis Pathology and TreatmentDiet, Metabolism, and Disease